Retinalamin
Retinalamin (Retina Bioregulator)
Retinalamin is a peptide bioregulator (cytamine) derived from bovine retinal tissue, developed by the St. Petersburg Institute of Bioregulation and Gerontology. It is primarily used to support retinal function, slow age-related macular degeneration, and aid recovery from various retinal pathologies including diabetic retinopathy, retinal dystrophies, and post-traumatic retinal damage. It belongs to the class of tissue-specific peptide bioregulators that have been studied extensively in Russian and Eastern European clinical research since the 1980s.
Mechanism of Action
Retinalamin exerts its effects through tissue-specific epigenetic regulation, binding to DNA in retinal cells and normalizing gene expression patterns that become dysregulated with age or disease. It promotes the synthesis of retinal-specific proteins, enhances photoreceptor cell metabolism, and supports the structural integrity of the outer nuclear layer and retinal pigment epithelium. Additionally, it demonstrates anti-apoptotic effects in retinal ganglion cells and improves microcirculation within retinal vasculature by modulating local cytokine signaling.
Evidence by Health Goal(6 goals)
Dosing Protocols
Administered as a parabulbar (periocular) injection, typically in a clinical or supervised setting
Cycle: One 10-day course; repeat courses every 3-6 months as needed
Clinical studies use parabulbar injection as the primary route for direct delivery to ocular tissues. Each vial typically contains 5mg lyophilized peptide. A full course is 10 injections (50mg total). Intramuscular administration has also been used in some protocols but parabulbar is preferred for ocular indications.
Safety & Side Effects
Retinalamin has a generally favorable safety profile based on several decades of clinical use in Eastern Europe, with no serious systemic adverse events reported in published literature at therapeutic doses. However, it is derived from bovine tissue and carries theoretical prion transmission concerns (though no cases have been documented), and parabulbar injection carries inherent procedural risks including infection or globe injury if not administered by trained personnel.
Possible Side Effects
- !Local injection site discomfort or mild bruising with parabulbar administration
- !Transient conjunctival irritation or redness following periocular injection
- !Mild eyelid swelling or chemosis in the first 24 hours post-injection
- !Rare hypersensitivity or allergic reaction to bovine-derived peptide components
- !Transient visual disturbance or blurring immediately following parabulbar injection
- !Mild headache reported in a small subset of patients during treatment courses
Interactions
- -May have additive or synergistic effects when combined with other retinal peptide bioregulators such as Vilon or Epithalamin - monitor for over-stimulation of repair pathways
- -Concurrent use with VEGF inhibitors (e.g., ranibizumab, bevacizumab) for macular degeneration is theoretically complementary but lacks formal pharmacokinetic interaction data
- -Use caution with systemic immunosuppressants as the peptide's immunomodulatory effects may be attenuated
- -Patients on anticoagulants (warfarin, heparin) should use caution given the parabulbar injection route and increased bruising risk
- -May enhance effects of other neuroprotective agents targeting retinal ganglion cells - combination data is limited to preclinical studies
Cost & Where to Buy
Retinalamin is produced primarily by Peptide Bioregulator companies (notably Cytomax/NPO Gerontology in Russia) and is available from Eastern European and some Western peptide vendors. A 10-vial course (5mg each) typically costs $60-$180 depending on source and import logistics. Repeated courses every 3-6 months reduce effective monthly cost. Availability in North America and Western Europe requires import from specialty suppliers.
Search on Amazon